NGD 981

Drug Profile

NGD 981

Latest Information Update: 07 Jan 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurogen Corporation
  • Developer Aventis Pharmaceuticals; Neurogen Corporation
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Corticotropin-releasing-hormone-Inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 07 Jan 2002 Discontinued-Preclinical for Depression in USA (Unknown route)
  • 21 Dec 2001 Neurogen and Aventis are collaborating in the development of the CRF antagonist programme
  • 11 Jan 2001 The CRF antagonist programme is available for licensing (http://www.neurogen.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top